Evidence map›Paper›PMID 29778783›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Intra-vitreal αB crystallin fused to elastin-like polypeptide provides neuroprotection in a mouse model of age-related macular degeneration.

Parameswaran G Sreekumar, Zhe Li, Wan Wang, Christine Spee, David R Hinton, Ram Kannan, J Andrew MacKay

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022
    Review
  14. Review
  15. Article
  16. Small Heat Shock Proteins in Retinal Diseases.Frontiers in molecular biosciences · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Parameswaran G SreekumarArnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Los Angeles, CA 90033, USA.
Zhe LiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA.
Wan WangDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA.
Christine SpeeDepartment Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
David R HintonDepartment Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA; Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Ram KannanArnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Los Angeles, CA 90033, USA.
J Andrew MacKayDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy of the University of Southern California, Los Angeles, CA 90089, USA; Department Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA; Department of Biomedical Engineering, Viterbi School of Engineering of the University of Southern California, Los Angeles, CA 90033, USA. Electronic address: jamackay@usc.edu.
University of Southern California · USDoheny Eye Institute · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
EXPERIMENTAL APPROACH TO MACULOPATHYR01EY001545 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HINTON, DAVID R. · 1985 to 2016
$6.0M
Intracellular switching using genetically engineered protein microdomainsR01GM114839 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACKAY, JOHN ANDREW · 2015 to 2019
$1.9M
NCATS NIH HHS UL1 TR000130NCATS NIH HHS UL1 TR001855NCI NIH HHS P30 CA014089NEI NIH HHS R01 EY001545NIGMS NIH HHS R01 GM114839
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible central vision loss, and the primary site of AMD pathology is the retinal pigment epithelium (RPE). Geographic atrophy (GA) is an advanced form of AMD characterized by extensive RPE cell loss, subsequent degeneration of photoreceptors, and thinning of retina. This report describes the protective potential of a peptide derived from the αB crystallin protein using a sodium iodate (NaIO

Indexed as

alpha-Crystallin B ChainAnimalsDisease Models, AnimalElastinEyeIntravitreal InjectionsIodatesMacular DegenerationMiceNeuroprotectionNeuroprotective AgentsPeptidesalpha-Crystallin B ChainElastinIodatesNeuroprotective AgentsPeptidessodium iodateElastin-like polypeptidesGeographic atrophyNaIO(3)Retinal degenerationRPE cell deathαB crystallin

Identifiers

PMID29778783
PMCPMC6368441
OpenAlexW2804524264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.